Alterations of the anaplastic lymphoma kinase (ALK), most commonly in form of a paracentric inversion resulting in an EML4-ALK fusion transcript, occur in about 4–6% of non-small cell lung cancer (NSCLC) [1, 2]. Here, ALK is linked to non-small cell lung carcinoma.